DelveInsight’s, “Chronic Obstructive Pulmonary Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Chronic Obstructive Pulmonary Disease Understanding
Chronic Obstructive Pulmonary Disease: Overview
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Excessive Smoking is the leading risk factor for COPD. In addition, occupational and environmental exposure to chemical fumes, dust, and other lung irritants accounts for 10–20% of cases. People with a history of severe lung infections in childhood are more likely to develop COPD. Also, α1 antitrypsin deficiency is a rare cause of COPD. The most common symptom of COPD is chronic and progressive dyspnea. Production of cough and sputum is present in up to 30% patient population. The symptoms may vary from day to day and may develop airflow limitation by many years. Diagnosis for COPD is primarily clinical. Most of the patients are diagnosed by primary care physicians. Screening is recommended with the occurrence and long-term persistence of symptoms such as chronic cough, excessive sputum production, and dyspnea, especially when these symptoms are accompanied by a history of cigarette smoking or regular exposure to occupational or environmental pollutants or toxins. Spirometry (used to assess the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways) is used to confirm the diagnosis of COPD in suspected cases. Currently, there is no cure for COPD; however, treatment can help slow disease progression rate and symptoms.
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines. The assessment part of the report embraces, in depth Chronic Obstructive Pulmonary Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters
This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Obstructive Pulmonary Disease Emerging Drugs
• Benralizumab: AstraZeneca
Benralizumab (FASENRA) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophil and attracts natural killer cells to induce rapid and near-complete depletion of eosinophil via apoptosis (programmed cell death). The drug is approved by the US FDA for asthma and is currently being developed for other respiratory and immunological disorders such as COPD, atopic dermatitis, and others. The drug was earlier in GALATHEA and TERRANOVA trials (randomized, double-blinded, placebo-controlled, parallel-group trials that assessed the safety and efficacy of Fasenra 30mg and 100mg for preventing COPD exacerbations). At present, the drug is in RESOLUTE (Phase III trial) to evaluate its efficacy and safety.
• MV130: Inmunotek S.L.
MV130 (BACTEK) is a bacterial mucosal vaccine or a bacterial polyvalent vaccine in a spray that is administered sublingually to treat recurrent respiratory tract infections in children and adults. MV130 plays a relevant role in modulating the functional activity of the innate and adaptive immune response by stimulating dendritic cells, which are part of innate immunity. A Phase III clinical trial is evaluating MV130 in patients with COPD. At present, the trial is ongoing in Spain.
• SB-240563: GlaxoSmithKline
SB-240563 (mepolizumab) is a humanized monoclonal antibody that blocks human interleukin 5 (hIL-5) from binding to its receptor. Initial clinical studies investigated the safety and efficacy of SB-240563 for the treatment of asthma and atopic dermatitis (AD). SB-240563 reduced peripheral and tissue eosinophils in patients with asthma and healthy volunteers. Currently, it is in the Phase III stage of the clinical trials.
• SAR440340: Sanofi/Regeneron
SAR440340 (Itepekimab) is a humanized IgG4P monoclonal antibody that blocks human interleukin 33 (hIL-33) from binding to its receptor. IL-33 is an epithelial cytokine that initiates and amplifies innate and adaptive type 2 and 1 inflammatory pathways in response to epithelial insults due to exposure to allergens, viruses, cigarette smoke, and pollutants. SAR440340 was invented using Regeneron's proprietary VelocImmune technology that yields optimized fully-human antibodies and is being developed jointly by Regeneron and Sanofi as part of a global collaboration agreement.
• CHF 6001: Chiesi Farmaceutici S.p.A.
CHF6001 is a novel inhaled phosphodiesterase-4 (PDE-4) inhibitor developed as an extrafine formulation (i.e., with mass median aerodynamic diameter ≤ 2 μm) and low systemic exposure. This allows CHF6001 to reach a therapeutic concentration in the target organ, the lung, with reduced systemic exposure, limiting systemic adverse effects. The drug is administered through a dry powder inhaler (DPI NEXThaler).
• YPL 001: Yungjin Pharm. Co., Ltd.
YPL 001 is a drug molecule that belongs to the anti-inflammatory and anti-histamine class of drugs. The drug is being developed for COPD. YPL-001 is a product developed using wild chives, which grow naturally in nature, as a raw material. A Phase II trial was conducted in US hospitals to assess the drug's safety in patients with moderate-to-severe COPD. In Phase I studies, YPL-001 was well tolerated in healthy subjects following single (up to 320 mg) and multiple (up to 240 mg twice daily [BID]) oral doses with no serious adverse events (AEs).
Further product details are provided in the report……..
Chronic Obstructive Pulmonary Disease: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Chronic Obstructive Pulmonary Disease
There are approx. 50+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.
DelveInsight’s report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Obstructive Pulmonary Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Obstructive Pulmonary Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Obstructive Pulmonary Disease drugs.
Chronic Obstructive Pulmonary Disease Report Insights
• Chronic Obstructive Pulmonary Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Chronic Obstructive Pulmonary Disease Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chronic Obstructive Pulmonary Disease drugs?
• How many Chronic Obstructive Pulmonary Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Obstructive Pulmonary Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Obstructive Pulmonary Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Obstructive Pulmonary Disease and their status?
• What are the key designations that have been granted to the emerging drugs?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook